Xerostomia - Pipeline Insight, 2024

This “Xerostomia - Pipeline Insight, 2024,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Xerostomia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Xerostomia Understanding

Xerostomia: Overview

Xerostomia is defined as dry mouth resulting from reduced salivary flow. Xerostomia is not a disease, but is a condition of various medical conditions like systemic lupus erythematosus, scleroderma, sarcoidosis, amyloidosis, Sjögren’s syndrome etc. It can also be due to the side effect of drugs like antihistamines, antidepressants, anticholinergics, anorexiants, and antihypertensives among others. The symptoms of Xerostomia include taste disorders (dysgeusia), painful tongue (glossodynia) and an increased need to drink water, bad breath, cheilitis, or inflammation and fissuring (splitting or cracking) of the lips, dryness in the mouth, fungal infections in the mouth, such as thrush, inflammation of the tongue, tongue ulcers, and more tooth decay and plaque. A diagnosis of Xerostomia is based on evidence obtained from the patient’s history, an examination of the oral cavity and/or sialometry. Treatment for Xerostomia depends on various factors such as whether the patient has an underlying condition or disease, or is taking certain medications that may be causing dry mouth.

Xerostomia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Xerostomia pipeline landscape is provided which includes the disease overview and Xerostomia treatment guidelines. The assessment part of the report embraces, in depth Xerostomia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Xerostomia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Xerostomia R&D. The therapies under development are focused on novel approaches to treat/improve Xerostomia.

Xerostomia Emerging Drugs Chapters

This segment of the Xerostomia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Xerostomia Emerging Drugs

LBS-020: Lubris BiopharmaLBS-020 is a recombinant lubricin and a glycoprotein stimulant. It is currently under Phase II development for the treatment of Xerostomia. Recombinant lubricin. Lubricin is a large endogenous complex glycoprotein that binds to, and protects tissue surfaces from friction.

AAV-AQP1: MeiraGTxAAV-AQP1 is an Adeno-associated virus vector containing gene therapy that contains the human aquaporin-1 gene (AAV2hAQP1) for the treatment of Xerostomia. It works on Aquaporin 1 replacement mechanism. It is currently under Phase I/II stage of development.

Xerostomia: Therapeutic Assessment

This segment of the report provides insights about the different Xerostomia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Xerostomia

There are approx. 2+ key companies which are developing the therapies for Xerostomia. The companies which have their Xerostomia drug candidates in the most advanced stage, i.e. Phase II include, Lubris Biopharma.

Phases

This report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Xerostomia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Xerostomia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Xerostomia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Xerostomia drugs.

Xerostomia Report Insights

• Xerostomia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Xerostomia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Xerostomia drugs?
• How many Xerostomia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Xerostomia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Xerostomia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Xerostomia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lubris Biopharma
• MeiraGTx

Key Products

• LBS-020
• AAV-AQP1